Rocket Pharmaceuticals (RCKT) EBT (2014 - 2026)

Rocket Pharmaceuticals has reported EBT for 13 years, with the latest figure at -$48.8 million in Q1 2026.

• Quarterly EBT rose 23.14% year-over-year to -$48.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$310.0 million (down 16.75% YoY) and the FY2025 annual result came in at -$361.6 million, up 8.22% from the prior year.
• EBT declined to -$48.8 million in Q1 2026 per RCKT's latest filing, from -$43.7 million in the prior quarter.
• Over five years, EBT peaked at -$43.7 million in Q4 2025 and troughed at -$190.8 million in Q3 2023.
• A 5-year average of -$100.4 million and a median of -$71.9 million in 2024 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2025: EBT surged 67.35% in 2022, then tumbled 64.86% in 2025.
• Over 5 years, EBT stood at -$68.3 million in 2022, then gained by 7.86% to -$62.9 million in 2023, then gained by 2.2% to -$61.6 million in 2024, then gained by 28.93% to -$43.7 million in 2025, then declined by 11.61% to -$48.8 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$48.8 million, -$43.7 million, and -$98.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.